Proinflammatory CD4+CD45RBhi lymphocytes promote mammary and intestinal carcinogenesis in ApcMin/+ mice

被引:70
作者
Rao, VP
Poutahidis, T
Ge, ZM
Nambiar, PR
Horwitz, BH
Fox, JG
Erdman, SE
机构
[1] MIT, Div Comparat Med, Cambridge, MA 02139 USA
[2] Brigham & Womens Hosp, Div Immunol Res, Dept Pathol, Boston, MA 02115 USA
[3] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA
[4] Aristotle Univ Thessaloniki, Fac Vet Med, Pathol Lab, GR-54006 Thessaloniki, Greece
关键词
D O I
10.1158/0008-5472.CAN-05-3445
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancers of breast and bowel are increasingly frequent in humans. Chronic inflammation is known to he a risk factor for these malignancies, yet cellular and molecular mechanisms linking inflammation and carcinogenesis remain poorly understood. Here, we apply a widely used T-cell transfer paradigm, involving adoptive transfer of proinflammatory CD4(+)CD45RB(hi) (T-E) cells to induce inflammatory bowel disease (IBD) in mice, to investigate roles of inflammation on carcinogenesis in the Apc(Min/+) mouse model of intestinal polyposis. We find that transfer of T-E cells significantly increases adenoma multiplicity and features of malignancy in recipient Apc(Min/+) mice. Surprisingly, we find that female Apc(Min/+) recipients of T-E cells also rapidly develop mammary tumors. Both intestinal polyposis and mammary adenocarcinoma are abolished by cotransfer of anti-inflaminatory CD4(+)CD45RB(lo) regulatory lymphocytes or by neutralization of key proinflammatory cytokine tumor necrosis factor-alpha. Lastly, down-regulation of cyclooxygenase-2 and c-Myc expression is observed coincident with tumor regression. These findings define a novel mouse model of inflammation-driven mammary carcinoma and suggest that epithelial carcinogenesis can be mitigated by anti-inflammatory cells and cytokines known to regulate IBD in humans and mice.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 29 条
[21]   REGULATORY INTERACTIONS BETWEEN CD45RB(HIGH) AND CD45RB(LOW) CD4(+) T-CELLS ARE IMPORTANT FOR THE BALANCE BETWEEN PROTECTIVE AND PATHOGENIC CELL-MEDIATED-IMMUNITY [J].
POWRIE, F ;
CORREAOLIVEIRA, R ;
MAUZE, S ;
COFFMAN, RL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :589-600
[22]   NSAIDs and chemoprevention [J].
Rao, CV ;
Reddy, BS .
CURRENT CANCER DRUG TARGETS, 2004, 4 (01) :29-42
[23]   Soluble mediators of inflammation during tumor development [J].
Robinson, SC ;
Coussens, LM .
ADVANCES IN CANCER RESEARCH, VOL 93, 2005, 93 :159-187
[24]   COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer [J].
Sabichi, AL ;
Lippman, SM .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :36-44
[25]   Control of intestinal inflammation by regulatory T cells [J].
Singh, B ;
Read, S ;
Asseman, C ;
Malmström, V ;
Mottet, C ;
Stephens, LA ;
Stepankova, R ;
Tlaskalova, H ;
Powrie, F .
IMMUNOLOGICAL REVIEWS, 2001, 182 :190-200
[26]  
SVENNEVIG JL, 1982, ACTA PATH MICRO IM A, V90, P131
[27]   Incidence of apoptosis increases with age in colorectal cancer [J].
Tanaka, K ;
Nagaoka, S ;
Takemura, T ;
Arai, T ;
Sawabe, M ;
Takubo, K ;
Sugihara, K ;
Kitagawa, M ;
Hirokawa, K .
EXPERIMENTAL GERONTOLOGY, 2002, 37 (12) :1469-1479
[28]   Tumor necrosis factor family members and inflammatory bowel disease [J].
Wang, J ;
Fu, YX .
IMMUNOLOGICAL REVIEWS, 2005, 204 :144-155
[29]   The role of cytokines in the epithelial cancer microenvironment [J].
Wilson, J ;
Balkwill, F .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (02) :113-120